As­pen looks to re­bound in pro­duc­tion and rev­enue af­ter Covid-19

Last year, South African-based vac­cine man­u­fac­tur­er As­pen Phar­ma­care was fac­ing re­ports that it had not re­ceived a sin­gle or­der for its man­u­fac­tured Covid-19 shots and that man­u­fac­tur­ing lines were sit­ting idle. But now the vac­cine pro­duc­er is look­ing to turn things around.

As­pen’s dis­clo­sure of its fi­nan­cial re­sults in March un­veiled that man­u­fac­tur­ing rev­enue had de­creased by 12% to R 603 mil­lion ($33.8 mil­lion), which Lor­raine Hill, As­pen Group’s COO, said is at­trib­ut­able to low­er Covid vac­cine sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER